Prana Provides Clinical Trials Safety and Progress Update

[Marketwired] – Prana Biotechnology today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been … more

View todays social media effects on PRAN

View the latest stocks trending across Twitter. Click to view dashboard

See who Prana is hiring next, click here to view